Co-101244

Co-101244 is a potent and selective small-molecule antagonist of the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the NR2B (GluN2B) subunit. Developed through a collaboration involving Pfizer, Purdue Neuroscience, and Senju Pharmaceutical, the compound was designed to provide neuroprotective and analgesic effects while minimizing the psychotomimetic and motor side effects typically associated with non-selective NMDA receptor blockade. Preclinical research has demonstrated its potential in treating Parkinson's disease, particularly when used in combination with adenosine A2A receptor antagonists to improve motor symptoms. Additionally, Co-101244 has been investigated for its role in modulating spinal reflex potentiation and cross-organ sensitization, suggesting potential applications in chronic pelvic pain, hyperalgesia, and irritable bowel syndrome. It has also been studied for its ability to attenuate withdrawal-induced cytotoxicity in models of alcoholism.